UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies

International journal of molecular sciences, 2021-12, Vol.22 (24), p.13185

2021

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers

Epilepsia (Copenhagen), 2015-11, Vol.56 (11), p.1723-1731

2015

Volltextzugriff (PDF)

Myoblast fusion in Drosophila

BioEssays, 2002-07, Vol.24 (7), p.591-601

2002

Volltextzugriff (PDF)

Characterization of Drosophila hibris, a gene related to human nephrin

Development (Cambridge), 2001-11, Vol.128 (21), p.4265-4276

2001

Volltextzugriff (PDF)

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study

NPJ schizophrenia, 2021-12, Vol.7 (1), p.63-63, Article 63

2021

Volltextzugriff (PDF)

M208. MEASURES OF COGNITION AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS RECEIVING SEP-363856

Schizophrenia bulletin, 2020-05, Vol.46 (Supplement_1), p.S215-S216

2020

Volltextzugriff (PDF)

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia

European archives of psychiatry and clinical neuroscience, 2023-10, Vol.273 (7), p.1543-1556

2023

Volltextzugriff (PDF)

Review of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist Ulotaront: Part II—Summary of Initial Clinical Efficacy/Safety Results

CNS spectrums, 2023-04, Vol.28 (2), p.221-221

2023

Volltextzugriff (PDF)

HEADWAY-DLB: A MULTINATIONAL STUDY EVALUATING THE SAFETY AND EFFICACY OF INTEPIRDINE (RVT-101) IN DEMENTIA WITH LEWY BODIES

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P936-P936

2017

Volltextzugriff (PDF)

Pharmacokinetics of USL261, a Novel Intranasal Formulation of Midazolam, in Subjects with Epilepsy (P3.285)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Safety and Pharmacodynamics of USL261, a Novel Intranasal Formulation of Midazolam, in Subjects with Epilepsy (P3.277)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Safety and Pharmacodynamics of USL261, a Novel Formulation of Midazolam Optimized for Intranasal Administration (P02.211)

Neurology, 2013-02, Vol.80 (7_supplement)

2013

Volltextzugriff (PDF)

Pharmacokinetics of USL261, a Novel Formulation of Intranasal Midazolam (P02.212)

Neurology, 2013-02, Vol.80 (7_supplement)

2013

Volltextzugriff (PDF)

Target recognition and synaptogenesis by motor axons: responses to the sidestep protein

International journal of developmental neuroscience, 2005-06, Vol.23 (4), p.397-410

2005

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics, and safety of USL 261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers

Epilepsia (Copenhagen), 2015-11, Vol.56 (11), p.1723-1731

2015

Volltextzugriff (PDF)

[P3–017]: HEADWAY‐DLB: A MULTINATIONAL STUDY EVALUATING THE SAFETY AND EFFICACY OF INTEPIRDINE (RVT‐101) IN DEMENTIA WITH LEWY BODIES

Alzheimer's & dementia, 2017-07, Vol.13 (7S_Part_19), p.P936-P936

2017

Volltextzugriff (PDF)

Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors

Current medical research and opinion, 2011-06, Vol.27 (6), p.1089-1096

2011

Volltextzugriff (PDF)

Pharmacological Profile and Therapeutic Potential of Ulotaront, a Novel Candidate for the Treatment of Schizophrenia

Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2022, Vol.96, p.2

2022

Volltextzugriff (PDF)

Understanding muscle development: Molecular mechanisms of myoblast fusion in Drosophila

Dworak, Heather A

2004

Volltextzugriff (PDF)

Generation of a high‐producing clone of a humanized anti‐B‐cell lymphoma monoclonal antibody (hLL2)

Cancer, 1997-12, Vol.80 (S12), p.2660-2666

1997

Volltextzugriff (PDF)

Developing and evaluating an asynchronous online library microcredential: a case study

Reference services review, 2020-11, Vol.48 (4), p.699-713

2020

Volltextzugriff (PDF)

Frequency, Etiology, and Impact of Unplanned Repeat Coronary Angiography After ST-Elevation Myocardial Infarction

The American journal of cardiology, 2022-01, Vol.163, p.1-7

2022

Volltextzugriff (PDF)

FDA Regulation of Neurological and Physical Medicine Devices: Access to Safe and Effective Neurotechnologies for All Americans

Neuron (Cambridge, Mass.), 2016-12, Vol.92 (5), p.943-948

2016

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(22)
Dissertationen
(1)

Sprache

Englisch
(23)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies

Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers

Myoblast fusion in Drosophila

Characterization of Drosophila hibris, a gene related to human nephrin

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study

M208. MEASURES OF COGNITION AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS RECEIVING SEP-363856

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia

Review of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist Ulotaront: Part II—Summary of Initial Clinical Efficacy/Safety Results

HEADWAY-DLB: A MULTINATIONAL STUDY EVALUATING THE SAFETY AND EFFICACY OF INTEPIRDINE (RVT-101) IN DEMENTIA WITH LEWY BODIES

Pharmacokinetics of USL261, a Novel Intranasal Formulation of Midazolam, in Subjects with Epilepsy (P3.285)

Safety and Pharmacodynamics of USL261, a Novel Intranasal Formulation of Midazolam, in Subjects with Epilepsy (P3.277)

Safety and Pharmacodynamics of USL261, a Novel Formulation of Midazolam Optimized for Intranasal Administration (P02.211)

Pharmacokinetics of USL261, a Novel Formulation of Intranasal Midazolam (P02.212)

Target recognition and synaptogenesis by motor axons: responses to the sidestep protein

Pharmacokinetics, pharmacodynamics, and safety of USL 261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers

[P3–017]: HEADWAY‐DLB: A MULTINATIONAL STUDY EVALUATING THE SAFETY AND EFFICACY OF INTEPIRDINE (RVT‐101) IN DEMENTIA WITH LEWY BODIES

Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors

Pharmacological Profile and Therapeutic Potential of Ulotaront, a Novel Candidate for the Treatment of Schizophrenia

Understanding muscle development: Molecular mechanisms of myoblast fusion in Drosophila

Generation of a high‐producing clone of a humanized anti‐B‐cell lymphoma monoclonal antibody (hLL2)

Developing and evaluating an asynchronous online library microcredential: a case study

Frequency, Etiology, and Impact of Unplanned Repeat Coronary Angiography After ST-Elevation Myocardial Infarction

FDA Regulation of Neurological and Physical Medicine Devices: Access to Safe and Effective Neurotechnologies for All Americans

Suchergebnisse filtern